Activity OverviewThe Virtual Lupus Clinic is a four-part series with case-based learning to help non-rheumatologists recognize, refer, and manage patients with lupus in conjunction with a rheumatologist. You will virtually examine four patients, each presenting with different symptoms, decide which labs to order, build the differential diagnosis, and decide next steps for treating the patient, including appropriate referrals, if needed.  This activity includes all cases: Case 1: A 40-year-old Asian female with facial rash, hair loss, fatigue, myalgias and a history of finger color changes in cold weather.Case 2: A 27-year-old Hispanic male with a history of thrombocytopenia and recurrent pleurisy coming in with malar rash, pleural friction rub concerning for pleurisy, and hand synovitis.Case 3: A 34-year-old Caucasian female with new onset HTN, pitting edema, weight gain, scarring alopecia, scarring rash on the nose, arthritis, and fatigue.Case 4: A 49-year-old African American female who presents with oral and nasal ulcers, arthritis, and fatigue.Virtual Lupus Clinic SeriesThis activity is part of a series. See the other activities in the series below.Virtual Lupus Clinic: All CasesVirtual Lupus Clinic – Case 1Virtual Lupus Clinic – Case 2Virtual Lupus Clinic – Case 3Virtual Lupus Clinic – Case 4Registration is complimentary.Target AudienceNon-rheumatologist physicians, primary care providers, physician assistants, and advanced practice nurses.Learning ObjectivesCase 1Upon completion of this activity, participants should be able to: Identify classic and atypical presentations of lupus, focusing on patient history, signs, symptoms, and physical examination findingsIdentify and interpret lab studies typically utilized in a new patient workup sent when evaluating a new patient with lupusEffectively communicate results of initial evaluation to patients, including strategies to ensure effective handoff to a specialist, if appropriateIdentify other common disease processes that may mimic lupus Case 2Upon completion of this activity, participants should be able to: Identify classic and atypical presentations of lupus, focusing on patient history, signs, symptoms, and physical examination findingsIdentify and interpret lab studies typically utilized in a new patient workup sent when evaluating a new patient with lupusProvide self-management and health maintenance education to patients Case 3Upon completion of this activity, participants should be able to: Identify classic and atypical presentations of lupus, focusing on patient history, signs, symptoms, and physical examination findingsIdentify and interpret lab studies typically utilized in a new patient workup sent when evaluating a new patient with lupusEffectively communicate results of initial evaluation to patients, including strategies to ensure effective handoff to a specialist, if appropriateRecall when to properly refer a patient to rheumatology in a timely manner   Case 4Upon completion of this activity, participants should be able to: Identify classic and atypical presentations of lupus, focusing on patient history, signs, symptoms, and physical examination findingsIdentify and interpret lab studies typically utilized in a new patient workup sent when evaluating a new patient with lupusRecognize signs and symptoms that may indicate a lupus flareUse high-yield lupus-specific questions and physical examination findings to help identify if a patient is in an active lupus flare and how to initiate appropriate flare treatment while awaiting a rheumatology referralProvide counseling and anticipatory guidance for patients in whom lupus is suspected and an initial referral to rheumatology is madeCE & MOC InformationCMEACCME Accreditation StatementThe American College of Rheumatology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. See the ACR's CME Mission Statement. For more information, download the AMA PRA Booklet.   AMA Designation StatementThe American College of Rheumatology designates this enduring material for a maximum of 4.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.CME credit must be claimed by February 1, 2027, at 11:59 PM ET.MOCMOC Recognition Statement: American Board of Internal Medicine (ABIM)Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.00 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. By completing this activity, you provide the ACR permission to share completion data with the ACCME and the certifying board.  After submitting a reflective statement with key takeaways from the activity, MOC points will be applied for ABIM diplomates to the ABIM diplomate number and date of birth provided when you registered. Points are sent nightly to ACCME and then transferred to the ABIM Physician Portal. Please allow at least 48 hours for points to display in the portal.MOC points must be claimed by February 1, 2027, at 11:59 PM ET. Financial Relationship DisclosuresACR Disclosure StatementIt is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org. In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity. Nature of Financial RelationshipsAll individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to:Advisor or review panel memberConsultantEmployeeOfficer or Board MemberGrant/research supportSpeaker/honoraria includes speaker’s bureau, symposia, and expert witnessIndependent contractorExecutive role and/or ownership interestRoyalties and/or patent beneficiaryIntellectual property/patentsStock options or bond holdings in a for-profit corporation or self-directed pension planPrivate investigatorExpert witnessEquity interestOther: specify details  None: Has no relevant financial relationship(s) with ineligible companies to disclose. All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated. Petros Efthimiou, MD (Planner) – Springer7, Uptodate7, Pfizer5, Amgen5, Sanofi5, Kiniksa5M. Brad Nelson, MD, MPH (Planner) – NoneB. Anne Eberhard, MBBS (Planner) – NoneParastoo Fazeli, MD (Planner) – NoneSchartess Culpepper Pace, MD (Planner) – NoneNina Ramessar, MD (Planner) – GlaxoSmithKline8Kimberly DeQuattro, MD (Reviewer) – Kyverna Pharmaceuticals5, GlaxoSmithKline5Shivani Garg, MD (Reviewer) – NoneKatie Chiseri, MPH, MCHES, PMP- Reviewer - NoneAcknowledgement of Commercial SupportThis activity is supported by the Centers for Disease Control and Prevention (CDC) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award of $7 million with 100 percent funded by CDC/HHS. The activity content was provided by the author(s) and does not necessarily represent the official views of, nor an endorsement by, the CDC/HHS or U.S. Government.See industry engagement opportunities and benefits of supporting the ACR.Educational Activity PoliciesSee ACR educational activity policies, including the online enduring activity refund policy.

Activity OverviewThe Virtual Lupus Clinic is a four-part series with case-based learning to help non-rheumatologists recognize, refer, and manage patients with lupus in conjunction with a rheumatologist. You will virtually examine four patients, each presenting with different symptoms, decide which labs to order, build the differential diagnosis, and decide next steps for treating the patient, including appropriate referrals, if needed.Case 1: A 40-year-old Asian female with facial rash, hair loss, fatigue, myalgias and a history of finger color changes in cold weather.Virtual Lupus Clinic Series This activity is part of a series. See the other activities in the series below.Virtual Lupus Clinic: All CasesVirtual Lupus Clinic – Case 2Virtual Lupus Clinic – Case 3Virtual Lupus Clinic – Case 4Registration is complimentary.Target AudienceNon-rheumatologist physicians, primary care providers, physician assistants, and advanced practice nurses.Learning ObjectivesUpon completion of this activity, participants will be able to:Identify classic and atypical presentations of lupus, focusing on patient history, signs, symptoms, and physical examination findingsIdentify and interpret lab studies typically utilized in a new patient workup sent when evaluating a new patient with lupusEffectively communicate results of initial evaluation to patients, including strategies to ensure effective handoff to a specialist, if appropriateIdentify other common disease processes that may mimic lupusCE & MOC InformationCMEACCME Accreditation StatementThe American College of Rheumatology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. See the ACR's CME Mission Statement. For more information, download the AMA PRA Booklet. AMA Designation StatementThe American College of Rheumatology designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.CME credit must be claimed by February 1, 2027, at 11:59 PM ET.MOCMOC Recognition Statement: American Board of Internal Medicine (ABIM) Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. By completing this activity, you provide the ACR permission to share completion data with the ACCME and the certifying board.  After submitting a reflective statement with key takeaways from the activity, MOC points will be applied for ABIM diplomates to the ABIM diplomate number and date of birth provided when you registered. Points are sent nightly to ACCME and then transferred to the ABIM Physician Portal. Please allow at least 48 hours for points to display in the portal.MOC points must be claimed by February 1, 2027, at 11:59 PM ET.Financial Relationship DisclosuresACR Disclosure StatementIt is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org. In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity. Nature of Financial Relationships All individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to:Advisor or review panel memberConsultantEmployeeOfficer or Board MemberGrant/research supportSpeaker/honoraria includes speaker’s bureau, symposia, and expert witnessIndependent contractorExecutive role and/or ownership interestRoyalties and/or patent beneficiaryIntellectual property/patentsStock options or bond holdings in a for-profit corporation or self-directed pension planPrivate investigatorExpert witnessEquity interestOther: specify details  None: Has no relevant financial relationship(s) with ineligible companies to disclose. All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated.  Petros Efthimiou, MD (Planner) – Springer7, Uptodate7, Pfizer5, Amgen5, Sanofi5, Kiniksa5M. Brad Nelson, MD, MPH (Planner) – NoneB. Anne Eberhard, MBBS (Planner) – NoneParastoo Fazeli, MD (Planner) – NoneSchartess Culpepper Pace, MD (Planner) – NoneNina Ramessar, MD (Planner) – GlaxoSmithKline8Kimberly DeQuattro, MD (Reviewer) – Kyverna Pharmaceuticals5, GlaxoSmithKline5Shivani Garg, MD (Reviewer) – NoneKatie Chiseri, MPH, MCHES, PMP- Reviewer - NoneAcknowledgement of Commercial SupportThis activity is supported by the Centers for Disease Control and Prevention (CDC) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award of $7 million with 100 percent funded by CDC/HHS. The activity content was provided by the author(s) and does not necessarily represent the official views of, nor an endorsement by, the CDC/HHS or U.S. Government.See industry engagement opportunities and benefits of supporting the ACR.Educational Activity PoliciesSee ACR educational activity policies, including the online enduring activity refund policy.

Activity OverviewThe Virtual Lupus Clinic is a four-part series with case-based learning to help non-rheumatologists recognize, refer, and manage patients with lupus in conjunction with a rheumatologist. You will virtually examine four patients, each presenting with different symptoms, decide which labs to order, build the differential diagnosis, and decide next steps for treating the patient, including appropriate referrals, if needed.Case 2: A 27-year-old Hispanic male with a history of thrombocytopenia and recurrent pleurisy coming in with malar rash, pleural friction rub concerning for pleurisy, and hand synovitis.Virtual Lupus Clinic SeriesThis activity is part of a series. See the other activities in the series below.Virtual Lupus Clinic: All CasesVirtual Lupus Clinic – Case 1Virtual Lupus Clinic – Case 2Virtual Lupus Clinic – Case 3Registration is complimentary.Target AudienceNon-rheumatologist physicians, primary care providers, physician assistants, and advanced practice nurses.Learning ObjectivesUpon completion of this activity, participants should be able to:Identify classic and atypical presentations of lupus, focusing on patient history, signs, symptoms, and physical examination findingsIdentify and interpret lab studies typically utilized in a new patient workup sent when evaluating a new patient with lupusProvide self-management and health maintenance education to patientsCE & MOC InformationCMEACCME Accreditation StatementThe American College of Rheumatology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. See the ACR's CME Mission Statement. For more information, download the AMA PRA Booklet. AMA Designation StatementThe American College of Rheumatology designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.CME credit must be claimed by February 1, 2027, at 11:59 PM ET.MOCMOC Recognition Statement: American Board of Internal Medicine (ABIM) Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. By completing this activity, you provide the ACR permission to share completion data with the ACCME and the certifying board.  After submitting a reflective statement with key takeaways from the activity, MOC points will be applied for ABIM diplomates to the ABIM diplomate number and date of birth provided when you registered. Points are sent nightly to ACCME and then transferred to the ABIM Physician Portal. Please allow at least 48 hours for points to display in the portal.MOC points must be claimed by February 1, 2027, at 11:59 PM ET.Financial Relationship DisclosuresACR Disclosure StatementIt is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org. In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity. Nature of Financial RelationshipsAll individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to: Advisor or review panel memberConsultantEmployeeOfficer or Board MemberGrant/research supportSpeaker/honoraria includes speaker’s bureau, symposia, and expert witnessIndependent contractorExecutive role and/or ownership interestRoyalties and/or patent beneficiaryIntellectual property/patentsStock options or bond holdings in a for-profit corporation or self-directed pension planPrivate investigatorExpert witnessEquity interestOther: specify details  None: Has no relevant financial relationship(s) with ineligible companies to disclose. All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated. Petros Efthimiou, MD (Planner) – Springer7, Uptodate7, Pfizer5, Amgen5, Sanofi5, Kiniksa5M. Brad Nelson, MD, MPH (Planner) – NoneB. Anne Eberhard, MBBS (Planner) – NoneParastoo Fazeli, MD (Planner) – NoneSchartess Culpepper Pace, MD (Planner) – NoneNina Ramessar, MD (Planner) – GlaxoSmithKline8Kimberly DeQuattro, MD (Reviewer) – Kyverna Pharmaceuticals5, GlaxoSmithKline5Shivani Garg, MD (Reviewer) – NoneKatie Chiseri, MPH, MCHES, PMP- Reviewer - NoneAcknowledgement of Commercial SupportThis activity is supported by the Centers for Disease Control and Prevention (CDC) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award of $7 million with 100 percent funded by CDC/HHS. The activity content was provided by the author(s) and does not necessarily represent the official views of, nor an endorsement by, the CDC/HHS or U.S. Government.See industry engagement opportunities and benefits of supporting the ACR.Educational Activity PoliciesSee ACR educational activity policies, including the online enduring activity refund policy.

Activity OverviewThe Virtual Lupus Clinic is a four-part series with case-based learning to help non-rheumatologists recognize, refer, and manage patients with lupus in conjunction with a rheumatologist. You will virtually examine four patients, each presenting with different symptoms, decide which labs to order, build the differential diagnosis, and decide next steps for treating the patient, including appropriate referrals, if needed.Case 3: A 34-year-old Caucasian female with new onset HTN, pitting edema, weight gain, scarring alopecia, scarring rash on the nose, arthritis, and fatigue.Virtual Lupus Clinic Series This activity is part of a series. See the other activities in the series below. Virtual Lupus Clinic: All CasesVirtual Lupus Clinic – Case 1Virtual Lupus Clinic – Case 2Virtual Lupus Clinic – Case 4Registration is complimentary.Target AudienceNon-rheumatologist physicians, primary care providers, physician assistants, and advanced practice nurses.Learning ObjectivesUpon completion of this activity, participants should be able to:Identify classic and atypical presentations of lupus, focusing on patient history, signs, symptoms, and physical examination findingsIdentify and interpret lab studies typically utilized in a new patient workup sent when evaluating a new patient with lupusEffectively communicate results of initial evaluation to patients, including strategies to ensure effective handoff to a specialist, if appropriateRecall when to properly refer a patient to rheumatology in a timely mannerCE & MOC InformationCMEACCME Accreditation StatementThe American College of Rheumatology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. See the ACR's CME Mission Statement. For more information, download the AMA PRA Booklet.   AMA Designation StatementThe American College of Rheumatology designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.CME credit must be claimed by February 1, 2027, at 11:59 PM ET.MOCMOC Recognition Statement: American Board of Internal Medicine (ABIM) Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. By completing this activity, you provide the ACR permission to share completion data with the ACCME and the certifying board.  After submitting a reflective statement with key takeaways from the activity, MOC points will be applied for ABIM diplomates to the ABIM diplomate number and date of birth provided when you registered. Points are sent nightly to ACCME and then transferred to the ABIM Physician Portal. Please allow at least 48 hours for points to display in the portal.MOC points must be claimed by February 1, 2027, at 11:59 PM ET.Financial Relationship DisclosuresACR Disclosure StatementIt is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org. In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity. Nature of Financial RelationshipsAll individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to:Advisor or review panel memberConsultantEmployeeOfficer or Board MemberGrant/research supportSpeaker/honoraria includes speaker’s bureau, symposia, and expert witnessIndependent contractorExecutive role and/or ownership interestRoyalties and/or patent beneficiaryIntellectual property/patentsStock options or bond holdings in a for-profit corporation or self-directed pension planPrivate investigatorExpert witnessEquity interestOther: specify details  None: Has no relevant financial relationship(s) with ineligible companies to disclose. All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated. Petros Efthimiou, MD (Planner) – Springer7, Uptodate7, Pfizer5, Amgen5, Sanofi5, Kiniksa5M. Brad Nelson, MD, MPH (Planner) – NoneB. Anne Eberhard, MBBS (Planner) – NoneParastoo Fazeli, MD (Planner) – NoneSchartess Culpepper Pace, MD (Planner) – NoneNina Ramessar, MD (Planner) – GlaxoSmithKline8Kimberly DeQuattro, MD (Reviewer) – Kyverna Pharmaceuticals5, GlaxoSmithKline5Shivani Garg, MD (Reviewer) – NoneKatie Chiseri, MPH, MCHES, PMP- Reviewer - NoneAcknowledgement of Commercial SupportThis activity is supported by the Centers for Disease Control and Prevention (CDC) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award of $7 million with 100 percent funded by CDC/HHS. The activity content was provided by the author(s) and does not necessarily represent the official views of, nor an endorsement by, the CDC/HHS or U.S. Government.See industry engagement opportunities and benefits of supporting the ACR.Educational Activity PoliciesSee ACR educational activity policies, including the online enduring activity refund policy.

Activity OverviewThe Virtual Lupus Clinic is a four-part series with case-based learning to help non-rheumatologists recognize, refer, and manage patients with lupus in conjunction with a rheumatologist. You will virtually examine four patients, each presenting with different symptoms, decide which labs to order, build the differential diagnosis, and decide next steps for treating the patient, including appropriate referrals, if needed.Case 4: A 49-year-old African American female who presents with oral and nasal ulcers, arthritis, and fatigue. Virtual Lupus Clinic Series This activity is part of a series. See the other activities in the series below.Virtual Lupus Clinic: All CasesVirtual Lupus Clinic – Case 1Virtual Lupus Clinic – Case 2Virtual Lupus Clinic – Case 3 Registration is complimentary.Target AudienceNon-rheumatologist physicians, primary care providers, physician assistants, and advanced practice nurses.Learning ObjectivesUpon completion of this activity, participants should be able to:Identify classic and atypical presentations of lupus, focusing on patient history, signs, symptoms, and physical examination findings.Identify and interpret lab studies typically utilized in a new patient workup sent when evaluating a new patient with lupus.Recognize signs and symptoms that may indicate a lupus flare.Use high-yield lupus-specific questions and physical examination findings to help identify if a patient is in an active lupus flare and how to initiate appropriate flare treatment while awaiting a rheumatology referral.Provide counseling and anticipatory guidance for patients in whom lupus is suspected and an initial referral to rheumatology is made.CE & MOC InformationCMEACCME Accreditation StatementThe American College of Rheumatology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. See the ACR's CME Mission Statement. For more information, download the AMA PRA Booklet. AMA Designation StatementThe American College of Rheumatology designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.CME credit must be claimed by February 1, 2027, at 11:59 PM ET.MOCMOC Recognition Statement: American Board of Internal Medicine (ABIM)Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. By completing this activity, you provide the ACR permission to share completion data with the ACCME and the certifying board.  After submitting a reflective statement with key takeaways from the activity, MOC points will be applied for ABIM diplomates to the ABIM diplomate number and date of birth provided when you registered. Points are sent nightly to ACCME and then transferred to the ABIM Physician Portal. Please allow at least 48 hours for points to display in the portal.MOC points must be claimed by February 1, 2027, at 11:59 PM ET.Financial Relationship Disclosures ACR Disclosure StatementIt is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org. In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity. Nature of Financial RelationshipsAll individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to:Advisor or review panel memberConsultantEmployeeOfficer or Board MemberGrant/research supportSpeaker/honoraria includes speaker’s bureau, symposia, and expert witnessIndependent contractorExecutive role and/or ownership interestRoyalties and/or patent beneficiaryIntellectual property/patentsStock options or bond holdings in a for-profit corporation or self-directed pension planPrivate investigatorExpert witnessEquity interestOther: specify details  None: Has no relevant financial relationship(s) with ineligible companies to disclose. All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated. Petros Efthimiou, MD (Planner) – Springer7, Uptodate7, Pfizer5, Amgen5, Sanofi5, Kiniksa5M. Brad Nelson, MD, MPH (Planner) – NoneB. Anne Eberhard, MBBS (Planner) – NoneParastoo Fazeli, MD (Planner) – NoneSchartess Culpepper Pace, MD (Planner) – NoneNina Ramessar, MD (Planner) – GlaxoSmithKline8Kimberly DeQuattro, MD (Reviewer) – Kyverna Pharmaceuticals5, GlaxoSmithKline5Shivani Garg, MD (Reviewer) – NoneKatie Chiseri, MPH, MCHES, PMP- Reviewer - NoneAcknowledgement of Commercial SupportThis activity is supported by the Centers for Disease Control and Prevention (CDC) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award of $7 million with 100 percent funded by CDC/HHS. The activity content was provided by the author(s) and does not necessarily represent the official views of, nor an endorsement by, the CDC/HHS or U.S. Government.See industry engagement opportunities and benefits of supporting the ACR.Educational Activity PoliciesSee ACR educational activity policies, including the online enduring activity refund policy.